PLX
Protalix BioTherapeutics, Inc. AMEX$2.13
Mkt Cap $171.6M
52w Low $1.32
43.3% of range
52w High $3.19
50d MA $2.45
200d MA $2.10
P/E (TTM)
-25.2x
EV/EBITDA
-33.5x
P/B
3.5x
Debt/Equity
0.2x
ROE
-13.7%
P/FCF
-10.4x
RSI (14)
—
ATR (14)
—
Beta
-0.09
50d MA
$2.45
200d MA
$2.10
Avg Volume
1.2M
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipel…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | 0.01 | -0.07 | -800.0% | 2.21 | +0.5% | +0.9% | -3.2% | -3.6% | -6.3% | -2.3% | +5.0% | — |
| Nov 13, 2025 | AMC | 0.06 | 0.03 | -50.0% | 1.93 | -11.4% | -3.6% | -2.1% | -2.6% | -8.3% | -9.8% | -9.8% | — |
| Aug 14, 2025 | AMC | 0.03 | 0.00 | -93.3% | 1.52 | +0.0% | -2.6% | +1.3% | +0.7% | +3.3% | +3.9% | +25.7% | — |
| May 9, 2025 | AMC | 0.08 | -0.05 | -162.5% | 1.72 | +0.6% | -15.1% | -3.5% | -2.9% | -2.9% | -2.9% | -10.5% | — |
| Mar 17, 2025 | AMC | 0.07 | 0.09 | +28.6% | 2.45 | +1.6% | -4.1% | -8.2% | -3.7% | +1.6% | +6.1% | +6.1% | — |
| Nov 14, 2024 | AMC | 0.06 | 0.03 | -50.0% | 1.41 | -2.1% | -0.7% | +17.7% | +15.6% | +19.9% | +17.7% | +24.1% | — |
| Aug 14, 2024 | AMC | -0.01 | -0.03 | -249.7% | 0.93 | +0.0% | +2.2% | +4.4% | +3.2% | +2.3% | +4.3% | +12.9% | — |
| May 10, 2024 | AMC | -0.02 | -0.06 | -200.0% | 1.10 | +2.7% | +3.6% | +5.5% | +2.7% | +6.4% | +3.6% | +8.2% | — |
| Mar 14, 2024 | AMC | -0.03 | -0.07 | -133.3% | 1.37 | +1.5% | -2.9% | -7.3% | -5.1% | -2.2% | -3.6% | -16.8% | — |
| Nov 6, 2023 | AMC | -0.07 | -0.04 | +42.9% | 1.51 | +1.3% | -0.7% | -9.3% | -7.9% | -11.3% | -10.6% | +5.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.21 | $2.22 | +0.5% | +0.9% | -3.2% | -3.6% | -6.3% | -2.3% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.71 | -1.7% | +0.6% | +0.6% | +2.9% | +5.2% | +2.3% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.43 | $2.36 | -2.9% | -0.4% | +3.7% | +9.9% | +10.7% | +9.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.37 | +1.5% | +1.5% | +4.4% | +3.0% | +3.7% | +3.0% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.49 | $1.48 | -0.7% | +12.1% | +8.7% | +13.4% | +24.2% | +1.3% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.59 | $3.96 | +10.3% | +7.2% | +7.2% | +5.6% | +1.7% | -1.1% |
| Apr 17 | Rodman & Renshaw | Maintains | Buy → Buy | — | $10.50 | $11.00 | +4.8% | +0.0% | -1.0% | -1.0% | -4.8% | -2.9% |
| Sep 6 | Jefferies | Maintains | Buy → Buy | — | $6.00 | $6.09 | +1.5% | +3.4% | +1.7% | -1.0% | +3.0% | +5.0% |
| Apr 4 | Rodman & Renshaw | Maintains | Buy → Buy | — | $8.40 | $8.90 | +6.0% | +2.7% | +0.0% | +6.0% | +5.9% | +7.1% |
| Apr 23 | Jefferies | Maintains | Buy → Buy | — | $20.80 | $21.30 | +2.4% | +6.7% | +7.2% | +1.9% | +2.9% | +5.8% |
Recent Filings
8-K
Unknown — 8-K Filing
PLX reported FY2025 results and clinical updates for its rare disease therapeutics, indicating operational progress that investors should monitor for pipeline advancement and cash runway sustainability in a capital-intensive biotech sector.
Mar 18
8-K
Protalix BioTherapeutics, Inc. -- 8-K Filing
Protalix announced a four-week dosing regimen for Elfabrio outside the US, which could potentially expand treatment convenience and market adoption for its Fabry disease therapy internationally.
Mar 9
8-K · 7.01
! Medium
Protalix BioTherapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Protalix BioTherapeutics furnished a corporate presentation for investor disclosure, providing updated company information through a Form 8-K filing.
Feb 11
Data updated apr 26, 2026 8:04pm
· Source: massive.com